EPI Health has graciously supported the COVID-19 News and Resource Center.
SECURE-Alopecia is a physician-entered patient registry to record COVID-19 positive alopecia patient outcomes, on or off treatment, with scarring and non-scarring alopecia. Clinicians worldwide are encouraged to report ALL cases of COVID-19 in their alopecia patients treated with antimalarials, JAK inhibitors (given the emergence of baricitinib as a potential trial COVID-19 therapy), and anti-androgens in particular, given emerging data.
To enable comparative analyses, the SECURE-Alopecia data entry platform is matched with SECURE-AD and closely aligned to PsoProtect, an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis, (a collaboration of the American Academy of Dermatology and the International League of Dermatological Societies) and other inflammatory disease registries. Collaborative discussions with these and other groups are ongoing.
As SECURE-Alopecia does not contain patient identifiable information, it is expected, like other COVID dermatology registries, to be exempt from IRB review, which is currently being validated in a number of jurisdictions.
SECURE-Alopecia has been endorsed by the World Congress of Hair Research, SPIN (Skin inflammation and Psoriasis International Network), the Australian Alopecia Areata Foundation, the American Hair Research Society (AHRS) and the International Society of Hair Restoration Surgery (ISHRS), and has engaged a global network of alopecia experts. More endorsements are currently being formalized and we would be delighted to receive further endorsements from national and international organizations. Please contact us at [email protected] if you are considering an endorsement so that we can recognize your support on our website and share patient information materials.
SECURE-Alopecia has been funded by the Irish not-for-profit company, NISR (National and International Skin Registry Solutions).
